2023
Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells. Kielbik M, Przygodzka P, Szulc-Kielbik I, Klink M. Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189003.doi: 10.1016/j.bbcan.2023.189003. Epub 2023 Oct 18.
Cytotoxic effects of halophilic archaea metabolites on ovarian cancer cell lines. Kowalewicz-Kulbat M, Krawczyk KT, Szulc-Kielbik I, Rykowski S, Denel-Bobrowska M, Olejniczak AB, Locht C, Klink M. Microb Cell Fact. 2023 Sep 28;22(1):197. doi: 10.1186/s12934-023-02206-y.
2022
Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment. Przygodzka P, Soboska K, Sochacka E, Pacholczyk M, Braun M, Kassassir H, Papiewska-Pająk I, Kielbik M, Boncela J. Cell Commun Signal. 2022; 20(1):193. doi: 10.1186/s12964-022-01003-1.
Polymorphonuclear Neutrophils and Tumors: Friend or Foe? Szulc-Kielbik I, Klink M. Exp Suppl. 2022;113:141-167. doi: 10.1007/978-3-030-91311-3_5.
Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful. Szulc-Kielbik I, Kielbik M. . Exp Suppl. 2022;113:107-140. doi: 10.1007/978-3-030-91311-3_4.
Chemokine expression in patients with ovarian cancer or benign ovarian tumors. Nowak M, Janas Ł, Soja M, Głowacka E, Szyłło K, Misiek M, Klink M. Arch Med Sci. 2022;18(3):682–689.
E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer. Kielbik M, Szulc-Kielbik I, Klink M. Int J Mol Sci. 2022; 23, 14383.
2021
Calreticulin – multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients. Kielbik M, Szulc-Kielbik I, Klink M. Cells. 2021; 10(1): E130.
Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells’ Cisplatin Resistance and EMT Markers Level. Kielbik M, Szulc-Kielbik I, Klink M. Int J Mol Sci. 2021; 22(2), 980.
The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188639.
Snail Overexpression Alters the microRNA Content of Extracellular Vesicles Released from HT29 Colorectal Cancer Cells and Activates Pro-Inflammatory State In Vivo. Papiewska-Pająk I, Przygodzka P, Krzyżanowski D, Soboska K, Szulc-Kiełbik I, Stasikowska-Kanicka O, Boncela J, Wągrowska-Danilewicz M, Kowalska MA. Cancers (Basel) 2021; 13(2): E172.
2020
The role of tumor‐associated macrophages in the progression and chemoresistance of ovarian cancer. Nowak M, Klink M. Cells. 2020; 9: 1299.
MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Wilczynski M, Kielbik M, Senderowska D, Krawczyk T, Szymanska B, Klink M, Bieńkiewicz J, Romanowicz H, Frühauf F, Malinowski A. Cancers (Basel) 2020; 12: E2680.
Determination of in vitro and in vivo immune response to recombinant cholesterol oxidase from Mycobacterium tuberculosis. Szulc-Kielbik I, Brzostek A, Gatkowska J, Kielbik M, Klink M. Immunol Lett. 2020; 228: 103-111.
2019
The potential role of iNOS in ovarian cancer progression and chemoresistance. Kielbik M, Szulc-Kielbik I, Klink M. Int J Mol Sci. 2019; 20 (7). pii: E1751. doi: 10.3390/ijms20071751.
Mycobacterium tuberculosis requires cholesterol oxidase to disrupt TLR2 signalling in human macrophages. Szulc-Kielbik I, Kielbik M, Przygodzka P, Brzostek A, Dziadek J, Klink M. Mediators Inflamm. 2019; 2019, ID 2373791.
IRAK1 and IRAK4 signaling proteins are dispensable in the response of human neutrophils to Mycobacterium tuberculosis infection. Kielbik M, Szulc-Kielbik I, Klink M. FEMS Microbiol Lett. 2019; 366(18). pii: fnz226.
Adenosine analogues as opposite modulators of the cisplatin resistance of ovarian cancer cells. Bednarska-Szczepaniak K, Krzyżanowski D, Klink M, Nowak M. Anticancer Agents Med Chem. 2019; 19: 473 – 486.
2018
Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients. Nowak M, Głowacka E, Lewkowicz P, Banasik M, Szyłło K, Zimna K, Bednarska K, Klink M. Immunobiology. 2018; 223: 1-7.
Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. Bednarska K, Król E, Glowacka E, Romanowicz H, Szyllo K, Klink M, Sulowska Z, Nowak M. Medicine. 2018; 97(12): e0180.
Cisplatin-induced ERK1/2 activity induces G1 to S phase progression results in chemoresistance of ovarian cancer cells. Kielbik M, Krzyzanowski D, Pawlik B, Klink M. Oncotarget. 2018; 9: 19847-19860.
Molecular typing of Mycobacterium kansasii using pulsed-field gel electrophoresis and newly designed variable-number tandem repeat analysis. Bakuła Z, Brzostek A, Borówka P, Żaczek A, Szulc-Kiełbik I, Podpora A, Parniewski P, Strapagiel D, Dziadek J, Proboszcz M, Bielecki J, van Ingen J, Jagielski T. Scientific Reports. 2018; 8: 4462.
